Huntington's disease phenocopies are clinically and genetically heterogeneous by Wild, EJ et al.
Wild, EJ; Mudanohwo, EE; Sweeney, MG; Schneider, SA; Beck, J; Bhatia, KP; Rossor, MN; 
Davis, MB; Tabrizi, SJ; (2008) Huntington's disease phenocopies are clinically and 
genetically heterogeneous. Movement Disorders , 23 (5) 716 - 720. 
 
ARTICLE 
 
Huntington’s disease phenocopies are clinically and genetically 
heterogeneous 
 
Edward J. Wild, MRCP;1† Ese E. Mudanohwo, BSc;2† Mary G. Sweeney, BSc;2 Susanne A. 
Schneider, MD;3 Jon Beck, PhD;1 Kailash P. Bhatia, FRCP, MD;3 Martin N. Rossor, FRCP, 
MD;2 Mary B. Davis, FRCPath, PhD;2 and Sarah J. Tabrizi, FRCP, PhD1* 
 
1 Department of Neurodegenerative Disease, 2 Neurogenetics Unit, 3 Sobell Department of 
Motor Neuroscience and Movement Disorders; UCL Institute of Neurology / National 
Hospital for Neurology and Neurosurgery, Queen Square, London, UK 
 
*To whom correspondence should be addressed at: National Hospital for Neurology and 
Neurosurgery, Queen Square, London WC1N 3BG. Tel: +44 (0) 8451 555 000. Fax: +44 (0) 
207 676 2180. Email: s.tabrizi@prion.ucl.ac.uk 
 
Word count: 3,057 words inclusive of abstract, tables, references and legends 
Abstract: 209 words 
† These authors contributed equally as first author. 
  
Abstract 
Purpose 
Huntington’s disease (HD) classically presents with movement disorder, cognitive 
dysfunction and behavioural problems but is phenotypically variable. 1% of patients with HD-
like symptoms lack the causative mutation and are considered HD phenocopies. Genetic 
diseases known to cause HD phenocopies include HD-like syndromes HDL1, HDL2 and 
HDL4 (SCA17). HD has phenotypic overlap with dentatorubral-pallidoluysian atrophy, the 
spinocerebellar ataxias and neuroferritinopathy. Identifying the genetic basis of HD 
phenocopies is important for diagnosis and may inform the search for HD genetic modifiers. 
We sought to identify neurogenetic diagnoses in the largest reported cohort of HD 
phenocopy patients. 
Methods 
285 patients with syndromes consistent with HD, who were HD expansion-negative, were 
screened for mutations in PRNP, JPH3, TBP, DRPLA, SCA1, SCA2, SCA3, FTL and FRDA. 
Results 
Genetic diagnoses were made in 8 subjects: we identified 5 cases of HDL4, 1 of HDL1 and 1 
of HDL2. One patient had Friedreich’s ataxia. There were no cases of DRPLA, SCA1, SCA2, 
SCA3 or neuroferritinopathy. 
Conclusions 
HD phenocopies are clinically and genetically diverse and a definitive genetic diagnosis is 
currently possible in only a minority of cases. When undertaken, it should be clinically 
directed and patients and clinicians should be prepared for the low probability of reaching a 
genetic diagnosis in this group of patients. 
Key words 
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Introduction 
Huntington’s disease (HD) is a fatal neurodegenerative disorder with autosomal dominant 
inheritance that typically presents with a triad of movement disorder, cognitive dysfunction 
and behavioural problems, but the disease can arise in the absence of a family history and 
its clinical presentation and course are highly variable.1 HD is caused by a CAG triplet 
expansion in the IT-15 gene encoding huntingtin.2 
Approximately 1% of subjects with symptoms and signs suggestive of HD do not have the 
HD expansion.3, 4 Such patients, referred to as HD phenocopies, present a diagnostic 
challenge. HD phenocopies are known to be produced by several neurogenetic syndromes5. 
These include the HD-like syndromes HDL1 (caused by an octapeptide repeat insertion in 
PRNP)6 and HDL2 (caused by mutations in JPH3).7 There is also clinical overlap between 
HD and dentatorubral-pallidoluysian atrophy (DRPLA)8 and the autosomal dominant 
spinocerebellar ataxias including SCA1, SCA2, SCA3, SCA12 and SCA17 (HDL4).9 
Friedreich’s ataxia has not previously been described as an HD phenocopy but is known to 
cause chorea.10 Neuroferritinopathy, caused by mutations in the ferritin light chain gene 
(FTL), is an autosomal dominant basal ganglia disease with features similar to those of 
HD.11  
 
Identifying the genetic basis of HD phenocopies is clinically important in the differential 
diagnosis of such patients, and has the potential to inform the search for genetic modifiers 
and intervention strategies for HD. 
 
From samples referred for HD genetic testing, we identified 285 patients with syndromes 
consistent with a diagnosis of HD, in whom the HD expansion was not detected. DNA 
samples were tested for the mutations causing HDL1, HDL2, DRPLA, SCA1, SCA2, SCA3, 
SCA17, neuroferritinopathy and FA. We present the outcome of these genetic tests and 
descriptions of the patients in whom genetic diagnoses were reached, as well as a brief 
review of the literature in HD phenocopies. 
 
Methods 
DNA was analysed from 285 consecutive patients with HD phenocopy syndromes whose 
samples were referred for genetic testing to the Clinical Neurogenetics service of the 
National Hospital for Neurology and Neurosurgery, London. The service receives referrals 
from neurology and neurogenetics clinics across the United Kingdom, with a particular focus 
in London and south-east UK. The majority of referrals (206 of 285) were from experienced 
consultant neurologists and neurogeneticists within the National Hospital for Neurology and 
Neurosurgery, which also has a nationwide catchment with a focus on London and the 
south-east UK. 
 
Subjects were defined as HD phenocopies on the basis of a clinical presentation consistent 
with HD when assessed by a consultant neurologist or neurogeneticist and a negative test 
for the pathogenic CAG repeat expansion in the gene encoding huntingtin. Clinical 
information was obtained from the abstract accompanying the referral, from hospital records 
and by direct communication with referring clinicians. 
 
An autosomal dominant family history was not an absolute requirement because HD may 
arise de novo because of CAG repeat expansion, or appear to do so where the family history 
is unavailable, incomplete or inaccurate. 
 
The choice of genetic tests to which samples were subjected was determined by those 
conditions previously screened for in HD phenocopy cohort studies12-15 and newly-described 
genetic causes of HD phenocopies (i.e. neuroferritinopathy). Because the cohort was drawn 
from patients whose DNA had been sent for genetic analysis following clinical assessment 
by experienced neurologists, we did not test for conditions that can readily be detected by 
clinical tests likely to have been performed already, such as neuroacanthocytosis (usually 
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excluded by examination of the blood film for acanthocytes16), Wilson’s disease (which 
causes biochemical and MRI abnormalities17) or PANK-2 (which causes characteristic MRI 
scan abnormalities18). Acanthocyte-negative cases of neuroacanthocytosis have been 
reported,19, 20 and it is therefore theoretically possible, though unlikely, that a VPS13A 
mutation may have been missed by our genetic tests. Benign hereditary chorea was not 
tested for because, though it is an hereditary cause of chorea, it is not known to cause 
cognitive impairment or psychiatric features.21, 22  
 
DNA was extracted using standard techniques using an NA3000 automated DNA extractor 
(AutoGen, MA). JPH3 (HDL2), TBP (SCA17/HDL4), DRPLA, ATXN1 (SCA1), ATXN2 
(SCA2) and ATXN3 (SCA3) were analysed by fluorescent PCR amplifying the triplet repeat 
region followed by size fractionation and fragment sizing using an Applied Biosystems 
3730XL genetic analyser and GeneMapper software (Applied Biosystems, CA). FTL exons 3 
and 4 (neuroferritinopathy) was analysed by sequence analysis and SeqScape software 
(Applied Biosystems). The PRNP octapeptide region was amplified by PCR, followed by 
electrophoresis on ethidium bromide stained agarose gels and viewed using a Gel Doc 1000 
transilluminator using Quantity One 4.5.1 software (both from Bio-Rad, CA). 1-OPRD and 6-
OPRI controls were run on each gel. Following the independent diagnosis of one patient in 
the cohort with Friedreich’s ataxia, the entire cohort was screened for FRDA expansions as 
described above. 
 
Results 
285 subjects met the criteria for HD phenocopy syndromes. Of these, 60 (21.1%) had a 
family history consistent with autosomal dominant inheritance. Positive genetic diagnoses 
were made in 8 subjects (2.8%). The clinical history and salient features of each diagnosed 
subject are described below and summarised in Table 2. Five subjects (1.8%) were found to 
have expansions in TBP causing SCA-17; one subject (0.4%) had a 6-octapeptide insertion 
in the PRNP gene consistent with familial prion disease; one subject was found to have 
HDL2 caused by a pathogenic expansion in JPH3; and one subject was subsequently 
diagnosed with Friedreich’s ataxia with a homozygous expansion in FXN. No cases of 
DRPLA, SCA1, SCA2, SCA3 or neuroferritinopathy were identified in this cohort. Screening 
the entire cohort for FRDA mutations revealed 4 heterozygous expansion carriers 
(consistent with the population frequency of 1 in 70) and no further homozygotes. 
Clinical features of the 8 genetically-diagnosed patients are summarised in Table 1 and full 
clinical case descriptions are available as supplementary data. 
 
Discussion 
In this series of 285 patients with HD phenocopy syndromes—the largest investigated to 
date—8 patients (2.8%) were identified with genetic mutations. SCA17 was the most 
commonly identified disorder (5 cases) with HDL2, familial prion disease and Friedreich’s 
ataxia also identified (1 case each). 
 
The commonest neurogenetic diagnosis in this cohort was SCA17. This causes intellectual 
deterioration, cerebellar ataxia, epilepsy and chorea, in 100, 90, 50 and 20% of patients 
respectively.12 All 5 SCA17 patients we report here presented with chorea and falls and 
developed ataxia and cognitive impairment, but cerebellar atrophy was not a universal 
feature on brain imaging. Thus, HD phenocopy patients represent an atypical subset of 
SCA17 cases. Within a given pedigree, SCA17 HD phenocopy syndromes are relatively 
phenotypically homogeneous.23 SCA17 is caused by CAG-CAA expansions in the TATA-box 
binding protein which is an important transcription initiation factor.24 This is of relevance to 
HD where transcriptional dysregulation occurs early in disease pathogenesis.25 
As well as being the largest HD phenocopy cohort studied to date, this study is the first time 
Friedreich’s ataxia (FA) has been described as an HD phenocopy. Unlike HD, FA has 
autosomal recessive inheritance, but a family history is not seen in all cases of HD because 
repeat length instability can cause HD to arise de novo, or a parent who would have become 
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symptomatic may die from other causes before onset.1  HD can produce cerebellar ataxia 
and atrophy26, 27 and chorea has been reported as a rare manifestation of FA10; but the 
unusual combination of chorea, eye movement restriction and cognitive impairment with the 
more classical findings of ataxia and sensory impairment has not previously been described 
in FA. Patient 7 had GAA repeat expansions in the FRDA gene of 850 and 76 repeats. 
Typically, FA patients have alleles of 600-1200 but the smallest reported disease-causing 
allele, which resulted in a typical FA phenotype, is 66 repeats.28 It is not known why a subset 
of FA patients develop chorea.10 
 
Familial prion disease is a rare cause of HD phenocopy syndromes. HDL1 is caused by an 
8-octapeptide insertion in the PRNP gene. All cases reported to date have had an eight-
octapeptide (192-nucleotide) insertion. Patient 6, who was felt to have presentation 
consistent with ataxic/rigid HD, was found to have a 6-octapeptide insertion (6-OPRI) in 
PRNP and was subsequently established to be a member of the largest known 6-OPRI 
pedigree.29 Even within a single pedigree, 6-OPRI mutations produce a variety of 
phenotypes including behavioural change, dementia, myoclonus, seizures, chorea and 
pyramidal, cerebellar and extrapyramidal signs.29 
 
HDL2, caused by CTG/CAG repeat expansions in JPH3, the gene encoding junctophilin-3, 
predominantly affects patients of African ancestry.15 It has not been described in Caucasian 
or Japanese subjects and, to our knowledge, patient 8 is the first report of a person of 
middle-eastern ancestry. 
 
This is also the first large cohort tested for mutations in FTL causing neuroferritinopathy. 
Autosomal dominantly inherited and causing chorea and cognitive impairment, it shares 
several features of HD. The absence of causative mutations from this and previous cohorts 
may be explained by the condition’s rarity and its association with relatively specific 
abnormal imaging findings.30 
 
Prior series of HD phenocopy patients from France, Portugal and Yugoslavia, tested for 
multiple genetic phenocopy syndromes, have reported varying rates of positive genetic 
diagnosis, between nil and 1.6%.12-14 In the largest previous series of 252 subjects, 2 cases 
each of HDL2 and SCA17 were identified. This cohort was not screened for mutations 
causing prion disease or neuroferritinopathy. Pooling the findings of our analysis with the 
three previous cohorts, the overall genetic discovery rate in 665 cases is 1.8%. Across 
cohorts, SCA17 represents 1.1% of HD phenocopy syndromes, and HDL1 and Friedreich’s 
ataxia each 0.2%. The frequency of HDL2 in HD phenocopy cases was examined in a large 
(582-patient) and clinically heterogeneous cohort from the USA and Japan.15 Pooling that 
series with our findings and the other European series, the frequency of HDL2 in the 1247 
cases reported is 0.7%. 
 
Our findings suggest principally that currently available genetic testing is unlikely to yield a 
diagnosis in HD-like patients where genetic testing for HD is negative. Detailed clinical 
assessment combined with directed clinical testing (e.g. blood films, biochemical tests and 
expertly interpreted MRI imaging) should therefore be the first resort in the assessment of 
such patients. Our findings do suggest a possible clinically-directed approach to genetic 
diagnosis in HD phenocopy syndromes but patients and clinicians should be prepared for 
the low probability that a diagnosis will be reached, and genetic testing should not be 
embarked upon blindly. SCA17 is a close clinical phenocopy and may be screened for in all 
HD phenocopy cases. Familial prion disease causes such a wide spectrum of motor 
abnormalities that mutations may be sought in HD phenocopies with cognitive decline. 
Friedreich’s ataxia may be suspected when ataxia or pyramidal signs are present and the 
inheritance is not clearly autosomal dominant. Junctophilin mutations may be sought in non-
caucasian patients with HD phenocopy syndromes. The possibility of neuroferritinopathy, 
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DRPLA and the other spinocerebellar ataxias should also be considered, although none of 
these have been found in any series of HD phenocopies described to date. 
 
In our cohort, as with other HD phenocopy populations,12-15 genetic diagnosis is possible in 
only a small minority of cases, suggesting that as-yet undescribed conditions account for the 
majority of HD phenocopies. We are currently assessing the patients from this cohort with 
autosomal dominant inheritance to try and identify novel HD phenocopy genes. 
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Tables 
Table 1 Clinical characteristics of subjects successfully diagnosed by genetic analysis in this 285-patient 
HD phenocopy cohort. 
 Patient 
 1 2 3 4 5 6 7 8 
Sex M F F F F F M F 
Diagnosis SCA17 SCA17 SCA17 SCA17 SCA17 Prion FA HDL2 
Age at onset 37 45 45 41 40 32 53 41 
Family History         
Autosomal dominant ● ● ●   ●   
None    ● ●  ● ● 
History         
Irritability ● ● ●     ● 
Aggression ● + +     ● 
Depression  +      ● 
Cognitive decline + + ● ● + + ● ● 
Falls  ●  ● ● + ● ● 
Gait disturbance  ● ● + ● ● ●  
Coordination problems    + ● + ●  
Dysarthria  + + + + + +  
Gait         
Postural instability  +   +    
Broad-based gait + + +    ●  
Tandem gait impairment + + + + + + ●  
Freezing  + +      
Eye movements         
Saccadic pursuits +    + +   
Delayed saccade initiation + + + +     
Slowed saccades     +    
Nystagmus      +   
Gaze restriction     +  +  
Speech / swallow         
Dysarthria + ● + + + + ●  
Dysphagia     +  +  
Limbs         
Limb ataxia +  + +  + ●  
Dystonia     +   + 
Chorea ● + ● ● ●  ● + 
Myoclonus  +       
Bradykinesia + + +  + +   
Brain imaging         
Global cortical atrophy + +   +   + 
Putaminal enhancement    +     
Cerebellar volume loss + +  +  +   
 
●, present at onset; +, present subsequently. 
 
